Balyasny Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Balyasny Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$513K	Sell	167,048 -501,126	-75%	-$1.94M	﹤0.01%	2352
2025 Q4	$2.73M	Buy	668,174 +105,726	+19%	+$524K	﹤0.01%	1718
2025 Q3	$2.74M	Buy	+562,448	New	+$2.95M	﹤0.01%	1658
2025 Q2	–	Sell	-652,644	Closed	-$3.45M	–	3276
2025 Q1	$3.45M	Buy	+652,644	New	+$4.76M	0.01%	1431
2024 Q3	–	Sell	-245,210	Closed	-$1.84M	–	3108
2024 Q2	$1.84M	Buy	+245,210	New	+$2.14M	﹤0.01%	1565
2023 Q3	–	Sell	-800,320	Closed	-$5.98M	–	2662
2023 Q2	$5.98M	Buy	800,320 +733,334	+1,095%	+$5.13M	0.01%	995
2023 Q1	$447K	Sell	66,986 -84,353	-56%	-$669K	﹤0.01%	1980
2022 Q4	$1.17M	Buy	+151,339	New	+$1.48M	﹤0.01%	1601

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's RXRX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 75% in Q1 2026, selling an estimated $1.94M and leaving 167,048 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

Balyasny Asset Management first reported a position in RXRX in Q4 2022 and has held it in 8 quarters since. The position peaked at $5.98M in Q2 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Balyasny Asset Management held 167,048 shares of Recursion Pharmaceuticals worth $513K as of Q1 2026.
Balyasny Asset Management sold 501,126 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.94M.
Recursion Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2352 holding.
Balyasny Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Balyasny Asset Management's Recursion Pharmaceuticals position peaked at $5.98M in Q2 2023.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.